


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE AND
TAKEDA ACHIEVED STRATEGIC AI-POWERED DRUG DISCOVERY
COLLABORATION WORTH UP TO USD600 MILLION**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, Insilico Medicine and Takeda (the “**Takeda**”), have entered into a strategic collaboration agreement to use Insilico Medicine’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across Takeda’s therapeutic areas, aiming to discover novel, clinically differentiated drug candidates for promising therapeutic targets (the “**Collaboration**”).

In this Collaboration, Insilico Medicine will lead AI-driven discovery to identify molecules meeting predefined scientific and early development criteria, while Takeda will apply its global development capabilities to advance selected candidates through clinical validation.

Under the terms of the relevant agreement, Insilico Medicine will receive approximately USD60 million in project initiation fees, near-term payments and milestones, and is eligible for success-based preclinical, clinical, commercial and sales milestone payments that could bring the total deal value to approximately USD600 million, plus tiered royalties on future sales. The agreement grants Takeda exclusive worldwide rights to develop, manufacture, and commercialize novel therapeutics selected through the Collaboration.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. Takeda aims to discover and deliver life-transforming treatments in its core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with its partners, Takeda aims to improve the patient experience and advance a new frontier of treatment options through its dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, Takeda is guided by its commitment to patients, its people and the planet. Takeda's employees in approximately 80 countries and regions are driven by its purpose and are grounded in the values that have defined Takeda for more than two centuries. For more information, visit www.takeda.com.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, July 2, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.